drugset / Trial / NCT02543645
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining varlilumab and atezolizumab. Phase l of the study will enroll patients with a number of tumor types; Phase ll will enroll only patients with renal cell carcinoma (RCC).\* \*Note: This Study was terminated prior to initiation of Phase II
Timeline
- Start
- 2015-10
- Primary completion
- 2017-04
- Completion
- 2017-05-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | — |
| Subject | Varlilumab | Monoclonal antibody | 0.3 mg/kg | — |
| Subject | Varlilumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Varlilumab | Monoclonal antibody | 3 mg/kg | — |